Materia Medica Holding has been present in the pharmaceutical market since 1992.
We have created a new class of medications based on a unique technology.
See moreRussia’s top 10 pharmaceutical companies
Our medications are known in 18 countries worldwide
Our Company’s portfolio includes over 30 medications
Our workforce exceeds 1,400 employees
International quality certificate
Award of the Government of the Russian Federation. See more
Green Cross Pharmaceutical Award. See more
Platinum Ounce Award. See more
Product of the Year Award.
See more
2006
Our team were bestowed the Award of the Government of the Russian Federation in science and technology for the creation, manufacturing and introduction into medical practice of new highly effective medications based on ultralow doses of antibodies to endogenous regulators.
2007
The Company’s team of employees were bestowed the Award of the Government of the Russian Federation in science and technology for the development and introduction into medical practice of a new selective anxiolytic based on antibodies to S100 protein.
2018, 2019, 2020, 2021
The medications manufactured by Materia Medica Holding have won Green Cross, a professional pharmacy award, on multiple occasions. The best of the best in the domestic pharmaceutical market are selected by a panel of over 1,200 judges who serve on the award’s Expert Council; those are leaders and senior executives of pharmacy chains, distributors, pharmaceutical and analytical companies, educational institutions, professional associations and media outlets.
2018
Materia Medica Holding took a prize of Platinum Ounce, the 18th Russian nationwide open competition of pharmaceutical professionals, in the category “Development of innovative medicines and their introduction into medical practice.”
2020, 2021
The medications manufactured by Materia Medica Holding have won the prestigious Product of the Year Award more than once. Consumer sympathy is the main criterion for selecting the winners of that prize. Throughout the year, leading research agencies compare sales in various market segments. The firms taking the lead are acclaimed as winners and receive the Product of the Year badge of honor—a five-pointed star-shaped statuette.
Raphamin
Rengalin
Anaferon for children
The SIRIUS-2021 space experiment completed in Moscow, with Materia Medica Holding acting as a partner
04 июля
Raphamin acclaimed as best at Smartpharma Awards 2022
17 июня
Rengalin and Ergoferon praised as Products of the Year
18 ноября
Innovative antiviral medication Raphamin gets registered in Russia
03 ноября
Cough medicine Rengalin recognized Brand of the Year No. 1 in Russia
29 октября
